Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) Director Acquires $24,600.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Gary Gordon acquired 10,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were bought at an average cost of $2.46 per share, with a total value of $24,600.00. Following the completion of the acquisition, the director directly owned 72,510 shares in the company, valued at $178,374.60. The trade was a 16.00% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

TriSalus Life Sciences Stock Performance

NASDAQ TLSI opened at $3.24 on Thursday. TriSalus Life Sciences, Inc. has a 52-week low of $2.20 and a 52-week high of $7.95. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78. The company has a market capitalization of $198.64 million, a P/E ratio of -2.30 and a beta of 0.56. The company has a fifty day moving average of $4.09 and a 200-day moving average of $5.09.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million for the quarter, compared to the consensus estimate of $13.20 million. As a group, equities research analysts predict that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 6th. Weiss Ratings downgraded shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Lake Street Capital lowered their price target on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Institutional Trading of TriSalus Life Sciences

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its stake in TriSalus Life Sciences by 1.9% in the first quarter. Bank of America Corp DE now owns 201,719 shares of the company’s stock worth $807,000 after purchasing an additional 3,703 shares during the last quarter. Empire Financial Management Company LLC lifted its stake in TriSalus Life Sciences by 316.9% in the first quarter. Empire Financial Management Company LLC now owns 300,275 shares of the company’s stock worth $1,201,000 after purchasing an additional 228,248 shares during the last quarter. First Light Asset Management LLC bought a new stake in TriSalus Life Sciences in the first quarter worth $20,267,000. Renaissance Technologies LLC bought a new stake in TriSalus Life Sciences in the first quarter worth $124,000. Finally, Sei Investments Co. bought a new stake in TriSalus Life Sciences in the first quarter worth $275,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.